Azitra, Inc. (AZTR)
| Market Cap | 4.44M +182.4% |
| Revenue (ttm) | n/a |
| Net Income | -12.27M |
| EPS | -9.84 |
| Shares Out | 6.06M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 109,261 |
| Open | 0.7425 |
| Previous Close | 0.7251 |
| Day's Range | 0.7425 - 0.7600 |
| 52-Week Range | 0.5180 - 4.5600 |
| Beta | -0.89 |
| Analysts | n/a |
| Price Target | 6.50 (+787.37%) |
| Est. Earnings | Nov 20, 2026 |
About AZTR
Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and topical live biotherapeutic products to treat skin diseases in the United States. The company develops ATR-04, a genetically modified strain of S. epidermidis that is in a Phase 1/2 clinical trial for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor targeted therapy; ATR-12, a genetically modified strain of S. epidermidis, which is in a Ph... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
The average 12-month stock price target for AZTR is $6.5, which is an increase of 787.37% from the latest price.
News
Azitra expands eligibility for Phase 1/2 clinical trial of ATR-04
Azitra (AZTR) announced amendments to its ongoing Phase 1/2 clinical trial of ATR04-484 that expand patient eligibility to include individuals with rash associated with KRAS and MEK inhibitors. The ex...
Azitra, Inc. Expands Eligibility for ATR-04 Phase 1/2 Clinical Trial to Include Patients with Rashes due to KRAS and MEK Inhibitors
Expanded eligibility significantly broadens potential treatment opportunities for ATR-04 beyond EGFR inhibitor-associated skin rash Additional protocol modifications expected to facilitate patient rec...
Azitra’s ATR-COSF shows skin revitalizing effectivity in ex vivo study
Azitra (AZTR) COO Travis Whitfill will present progress for its cosmetic ATR-COSF program targeting the appearance of fine lines and wrinkles at the BIO-Europe conference in Cologne on November 10th.
Azitra, Inc. Announces Revitalizing Results from Ex Vivo Study of ATR-COSF Demonstrating Ability to Reduce Fine Lines and Improve Elasticity in Human Skin
ATR-COSF uses a supernatant based formulation containing an active recombinant human domain of the protein, filaggrin. Ex vivo data in two models of recent cosmetic surgery explants showed visible imp...
Azitra announces 1-for-10 reverse stock split
Azitra (AZTR) announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 10 pre-split shares. The reverse…
Azitra, Inc. Announces Reverse Stock Split
Common Stock Will Begin Trading on a Split-Adjusted Basis on October 26, 2026 BRANFORD, Conn., Oct. 16, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical comp...
Azitra completes Cohort 1 in Phase 1/2 clinical trial evaluating ATR04-484
Azitra (AZTR) announced the completion of Cohort 1 in its Phase 1/2 clinical trial evaluating ATR04-484 as a potential treatment for EGFR inhibitor-associated skin rash. Following its review of availa...
Azitra, Inc. Advances ATR-04 Phase 1/2 Clinical Trial to Cohort 2 Following Safety Review Committee Clearance
BRANFORD, Conn., Oct. 1, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra" or the "Company") (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for ...
Azitra Transcript: H.C. Wainwright 28th Annual Global Investment Conference
The company presented its precision dermatology platforms, highlighting engineered skin bacteria and AI-driven drug discovery. Key programs include ATR-04 for EGFR inhibitor-associated rash in phase I/II trials and ATR-COSF for cosmetic use, both with clinical milestones expected later this year.
Azitra, Inc. to Present at the H.C. Wainwright 28th Annual Global Investment Conference
BRANFORD, Conn., Sept. 8, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra" or the "Company") (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for...
Azitra regains NYSE American compliance
Azitra (AZTR) announced that it has received written notification from NYSE American confirming that the company has regained compliance with all of the NYSE American continued listing standards set f...
Azitra, Inc. Regains Compliance with NYSE American Continued Listing Standards
BRANFORD, Conn., Aug. 21, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra" or the "Company") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for...
Azitra Slides: Corporate presentation
Azitra has posted slides in relation to its latest quarterly earnings report, which was published on August 21, 2026.
Azitra reports Q2 EPS (17c) vs. ($1.18) last year
“The second quarter has marked an exciting evolution for Azitra (AZTR) with the first data from our ATR-COSF program, which provided validation of our strategy to leverage our microbial genetic…
Azitra, Inc. Announces Q2 2026 Results and Provides Business Updates
BRANFORD, Conn., Aug. 12, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra" or the "Company") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for...
Azitra Quarterly report: Q2 2026
Azitra has published its Q2 2026 quarterly earnings report on August 12, 2026.
Azitra Earnings release: Q2 2026
Azitra released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
Meet Azitra: Fly Exclusive with CEO Francisco Salva
In an exclusive interview, Azitra (AZTR) CEO Francisco Salva spoke with The Fly about the company’s expanding strategy, the science behind its recombinant protein programs, the commercial potential of...
Azitra building multi market microbial engineering platform, CEO says
14:00 EDT Azitra (AZTR) building multi market microbial engineering platform, CEO says
Azitra says Phase 1/2 ATR 04 trial remains on track for topline data this year
14:00 EDT Azitra (AZTR) says Phase 1/2 ATR 04 trial remains on track for topline data this year
CEO says breadth of Azitra’s platform opens multiple attractive markets
14:00 EDT CEO says breadth of Azitra’s (AZTR) platform opens multiple attractive markets
Azitra announces results from two ex vivo human skin tissue studies
Azitra (AZTR) announced results from two separate ex vivo human skin tissue studies. The studies evaluated the distribution and anti-wrinkle activity of Azitra’s filaggrin domain containing supernatan...
Azitra, Inc. Announces Breakthough Repeat Dose and Anti-Wrinkle Ex Vivo Results for ATR-COSF Program, Demonstrating Increased Distribution and Elasticity
ATR-COSF uses a supernatant based formulation containing an active recombinant human domain of the protein, filaggrin ("rHDfilaggrin"). This S. epidermis derived supernatant is in development as a hig...
Azitra Slides: Corporate presentation
Azitra has posted slides in relation to its latest quarterly earnings report, which was published on July 10, 2026.
Azitra, Inc. CEO Issues Letter to Shareholders Detailing Strategic Reorientation Initiatives and Outlook for 2026 and Beyond
BRANFORD, Conn., June 17, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra" or the "Company") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for...